ArticleCancer causes & control : CCC2026
Low muscle mass, obesity, and cause-specific mortality in cancer patients: a nationwide cohort study.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeLow muscle mass (LMM) is a risk factor for adverse health outcomes, but its prognostic relevance in cancer remains insufficiently studied. We investigated the independent and combined effects of LMM and obesity on mortality in cancer patients.
methodsThis cohort study included 635,867 cancer patients. LMM was defined as the lowest quartile on the appendicular skeletal muscle mass index (ASMI). Obesity was defined as body mass index ≥25 kg/m
resultsCompared with individuals in the highest ASMI quartile, LMM had significantly higher risks of all-cause (aHR 1.25, 95% CI 1.23-1.27), cancer-specific (aHR 1.21, 95% CI 1.19-1.23), cardiovascular (aHR 1.49, 95% CI 1.36-1.64), and respiratory mortality (aHR 2.26, 95% CI 1.99-2.56). While obesity was associated with lower mortality risks than non-obese status, the LMM with obesity group exhibited the highest risk for all-cause (aHR 1.22; 95% CI, 1.16-1.28) and cancer-specific mortality (aHR 1.22; 95% CI, 1.16-1.29).
conclusionsLMM was independently associated with increased mortality in cancer patients, regardless of obesity status. The adverse effect was amplified in those with both LMM and obesity, but obesity alone showed a modest inverse association. These findings highlight the clinical relevance of evaluating muscle mass and body composition in cancer.
Indexed as
Identifiers
42700202What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.